Deborah Ann Miller Sells 5,500 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) insider Deborah Ann Miller sold 5,500 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $107.84, for a total value of $593,120.00. Following the completion of the sale, the insider owned 59,634 shares in the company, valued at $6,430,930.56. This represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Deborah Ann Miller also recently made the following trade(s):

• On Thursday, April 30th, Deborah Ann Miller sold 5,500 shares of Nuvalent stock. The stock was sold at an average price of $99.22, for a total value of $545,710.00.

Nuvalent Stock Performance

NUVL stock traded down $17.38 during trading on Monday, hitting $93.01. The stock had a trading volume of 2,941,821 shares, compared to its average volume of 588,201. The stock has a market cap of $7.35 billion, a price-to-earnings ratio of -15.35 and a beta of 1.15. The company’s 50 day moving average price is $103.03 and its two-hundred day moving average price is $103.31. Nuvalent, Inc. has a 1-year low of $71.13 and a 1-year high of $113.01.

Nuvalent (NASDAQ:NUVL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($1.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($0.04). During the same period in the prior year, the business earned ($1.18) EPS. As a group, sell-side analysts forecast that Nuvalent, Inc. will post -5.74 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have commented on NUVL shares. Sanford C. Bernstein started coverage on shares of Nuvalent in a research note on Thursday, May 21st. They issued an “outperform” rating and a $189.00 target price for the company. Cantor Fitzgerald raised their price objective on Nuvalent from $135.00 to $140.00 and gave the stock an “overweight” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nuvalent in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and issued a $155.00 target price on shares of Nuvalent in a research note on Tuesday, April 21st. Finally, Wedbush reissued an “outperform” rating and issued a $125.00 price target on shares of Nuvalent in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $140.29.

Institutional Trading of Nuvalent

A number of institutional investors and hedge funds have recently made changes to their positions in NUVL. Vanguard Group Inc. raised its position in shares of Nuvalent by 13.9% in the 4th quarter. Vanguard Group Inc. now owns 5,244,271 shares of the company’s stock worth $527,521,000 after buying an additional 639,264 shares during the period. Wellington Management Group LLP increased its stake in Nuvalent by 7.0% during the fourth quarter. Wellington Management Group LLP now owns 2,461,823 shares of the company’s stock worth $247,635,000 after acquiring an additional 160,958 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Nuvalent by 32.9% during the fourth quarter. JPMorgan Chase & Co. now owns 2,205,251 shares of the company’s stock worth $221,826,000 after acquiring an additional 545,542 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Nuvalent by 18.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,146,938 shares of the company’s stock worth $215,962,000 after purchasing an additional 336,518 shares during the period. Finally, RA Capital Management L.P. lifted its stake in shares of Nuvalent by 50.8% in the 4th quarter. RA Capital Management L.P. now owns 1,880,057 shares of the company’s stock valued at $189,115,000 after purchasing an additional 633,601 shares in the last quarter. 97.26% of the stock is currently owned by institutional investors and hedge funds.

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.